Geben Sie eine Aktie oder eine Kryptowährung in der Suchleiste an, um eine Zusammenfassung zu erhalten
Lyell Immunopharma Inc
UndervaluedAbschluss
🧐 Extreme Unsicherheit, sehr hohes Risiko, untersuchen Sie alle Aspekte mit großer Sorgfalt, es gibt offensichtlich transparentere Unternehmen als Alternative.
Similar to Lyell Immunopharma Inc
4978
ReproCell IncACAD
ACADIA Pharmaceuticals IncMAGLE
Magle Chemoswed Holding AbATRY
Atrys Health SLPBYI
Puma Biotechnology IncLyell Immunopharma Inc
LYELLyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity; and Stim-R, a proprietary synthetic-cell mimetic. It is also developing IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate that is in Phase 1/2 clinical development for the treatment of patients with aggressive relapsed/refractory large B-cell non-Hodgkin lymphoma; and solid tumors program which is in preclinical trial targeting solid tumor indications. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California. Address: 201 Haskins Way, South San Francisco, CA, United States, 94080
Analytics
Zielpreis von Wall Street
0.80 USDKGV
–Dividendenrendite
–Schlüsselzahlen LYEL
- Gewinnspanne
- Gesamtumsatz
- Bruttogewinn
- Nettogewinn
Dividenden-Analyse LYEL
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y>5 - expected 5-9 dividend yield on cost over 10Y<5 - expected <5 dividend yield on cost over 10YMaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–Dividendenwachstum über 5 Jahre
–Kontinuierliches Wachstum
–Ausschüttungsquote 5-Jahres-Durchschnitt
–Verlauf der Dividende LYEL
- Auszahlungsquote
- Dividends
- Dividendenrendite
Bewertung der Aktie LYEL
- KUV
- KGV
- Kurs-Buchwert-Verhältnis
- Liquiditätsgrad
- Verschuldungsgrad
Finanzen LYEL
Ergebnisse | 31.12.2019 | 31.12.2020 | 31.12.2021 | 31.12.2022 | 31.12.2023 | 31.12.2024 | Dynamik | |
Gesamtumsatz | 657 000 USD | 7 756 000 USD | 10 650 000 USD | 84 683 000 USD | 130 000 USD | 61 000 USD | ||
Betriebseinnahmen | -102 089 000 USD | -211 937 000 USD | -214 776 000 USD | -183 118 000 USD | -247 008 000 USD | -3 309 000 USD | ||
Nettogewinn - (CF) | -121 256 000 USD | -198 533 000 USD | -285 501 000 USD | -4 754 000 USD | -234 632 000 USD | -342 994 000 USD | ||
Normalisiertes Basis-EPS | -0.49 USD | -0.81 USD | -1.18 USD | -0.02 USD | -0.93 USD | -1.31 USD | ||
Dividende pro Aktie | 0.00 USD | 0.00 USD | 0.00 USD | 0.00 USD | 0.00 USD | 0.00 USD | ||
Auszahlungsquote | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | ||
Gesamtvermögen | 555 631 000 USD | 908 280 000 USD | 1 127 406 000 USD | 937 561 000 USD | 750 029 000 USD | 490 859 000 USD | ||
Gesamtverbindlichkeiten | 147 576 000 USD | 189 840 000 USD | 197 619 000 USD | 104 309 000 USD | 95 077 000 USD | 108 035 000 USD | ||
Verschuldungsgrad | 0.27 | 0.21 | 0.18 | 0.11 | 0.13 | 0.22 | ||
Gesamtumlaufvermögen | 440 259 000 USD | 617 547 000 USD | 626 286 000 USD | 651 295 000 USD | 554 686 000 USD | 379 594 000 USD | ||
Gesamtverbindlichkeiten | 22 045 000 USD | 49 285 000 USD | 46 738 000 USD | 37 028 000 USD | 34 519 000 USD | 53 788 000 USD | ||
Liquiditätsgrad | 19.97 | 12.53 | 13.40 | 17.59 | 16.07 | 7.06 | ||
Schnellliquiditätsgrad | 19.97 | 12.53 | 13.40 | 17.59 | 16.07 | 7.06 | ||
ROA | -21.82 % | -21.86 % | -25.32 % | -0.51 % | -31.28 % | -69.88 % | ||
FFO-Zinsdeckung | - | -36.22 | -184.10 | - | - | - | ||
KGV - P/E (LTM) | - | - | -6.58 | -180.35 | -2.08 | -0.49 | ||
Dividendenrendite (LTM) | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | ||
Rückkaufrendite (LTM) | - | - | 1.56 % | -1.79 % | -1.58 % | -4.18 % |